Innovent Biologics (STU:6IB) Capex-to-Revenue : 0.22 (As of Dec. 2023)

Innovent Biologics Capex-to-Revenue Chart

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Revenue	Get a 7-Day Free Trial										0.62	0.21	0.39	0.23	0.22

Competitive Comparison of Innovent Biologics's Capex-to-Revenue

For the Biotechnology subindustry, Innovent Biologics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Capex-to-Revenue falls into.

Innovent Biologics Capex-to-Revenue Calculation

Innovent Biologics's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Innovent Biologics's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovent Biologics  (STU:6IB) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Innovent Biologics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (STU:6IB) Business Description